// App-Quantinova.ai

: CD19/CD3 bispecific antibodies induce potent response against chronic lymphocytic leukemia cells ex vivo

Researchers

Presenter

  • Hannah Ruth Robinson

Principal Investigators

  • Junpeng Qi

  • Sivasubramanian Baskar

  • Christoph Rader

  • Adrian Wiestner

Medical Centers

  • NHLBI, NIH

  • Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

  • Scripps Florida

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • B-cell acute lymphoblastic leukemia

  • Chronic Lymphocytic Leukemia

  • Acute lymphoblastic leukemia

  • Non-Hodgkin's Lymphoma

  • Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Lymphomas

Biomarkers

  • Cluster of Differentiation 4

  • Cluster of differentiation 8A

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Blinatumomab

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved